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The generation of tumor-directed cytotoxic T
lymphocytes is considered crucial for the induction
of antitumor immunity. To activate these CD8+
T cells, antigen-presenting cells (APCs) must initially
acquire tumor cell-associated antigens. The major
source of tumor antigens is dead tumor cells, but
little is known about how APCs in draining lymph no-
des acquire and crosspresent these antigens. Here
we show that CD169+ macrophages phagocytose
dead tumor cells transported via lymphatic flow
and subsequently crosspresent tumor antigens to
CD8+ T cells. Subcutaneous immunization with irra-
diated tumor cells protects mice from syngenic
tumor. However, tumor antigen-specific CD8+ T cell
activation and subsequent antitumor immunity are
severely impaired in mice depleted with CD169+
macrophages. Neithermigratory dendritic cells (DCs)
nor lymph node-resident conventional DCs are
essential for the crosspresentation of tumor anti-
gens. Thus, we have identified CD169+macrophages
as lymph node-resident APCs dominating early acti-
vation of tumor antigen-specific CD8+ T cells.
INTRODUCTION
During tumor growth, tumor cells accumulate genetic mutations
and acquire features that enable them to escape from the host
immune system in various ways. In addition to these intrinsic
properties of tumor cells that allow them to elude immune surveil-
lance, the environment within and around the tumor often has
adetrimental effect on the host immune system, including impair-
ment of dendritic cell (DC) function and suppression of T cells
caused by tumor-derived factors or myeloid-derived suppressor
cells infiltrating the tumors (Gabrilovich, 2004; Melief, 2008;
Sica and Bronte, 2007). This immunosuppressive environment
induced by tumors limits the effectiveness of anticancer chemo-
therapy and g-irradiation. Therefore, great efforts have been
made to enhance innate and acquired antitumor immunity.The generation of tumor antigen-specific cytotoxic T cells
(CTLs) is considered crucial for the induction of antitumor immu-
nity. To generate and activate T cell immunity against tumor anti-
gens, antigen-presenting cells (APCs) must initially acquire
tumor cell-associated antigens, and one of the major sources
of tumor antigens is dead tumor cells (Melief, 2008). Massive
tumor cell death induced by anticancer therapy and particulate
matter from the dead tumor cells provide large amounts of
tumor-associated antigens. However, previous studies have
been unable to clarify the mechanism by which APCs in the
lymph node (LN) internalize and crosspresent these types of anti-
gens to CD8+ T cells.
Phagocytes, such asmacrophages and DCs, swiftly phagocy-
tose apoptotic cells by recognizing molecules exposed only on
the surface of these corpses (Henson et al., 2001; Lauber
et al., 2004; Ravichandran and Lorenz, 2007; Savill and Fadok,
2000). Failure of apoptotic cell clearance results in autoimmune
disorders, indicating that apoptotic cell clearance by phagocytes
is essential for the maintenance of self-tolerance under physio-
logical conditions (Asano et al., 2004; Hanayama et al., 2004;
Miyanishi et al., 2007). Consistent with these findings, the intra-
venous injection of apoptotic cells can induce cell-associated
antigen-specific immunosuppression or tolerance (Green et al.,
2009). This mechanism of tolerance induction requires the
contributions of two populations of cells in the splenic marginal
zone (MZ): macrophages that rapidly clear corpses in the blood
flow, and CD8a+CD103+ DCs that selectively phagocytose dead
cell and subsequently present dead cell-associated antigen
(Miyake et al., 2007; Qiu et al., 2009).
In contrast to the outcome after intravenous injection, subcu-
taneously injected apoptotic cells are often immunogenic and
many investigators have taken advantage of immunogenic tumor
corpses for tumor vaccination (Apetoh et al., 2007; Green et al.,
2009; Obeid et al., 2007; Tesniere et al., 2008). These findings
suggest that apoptotic cells in the periphery are cleared and
processed in a very different way from blood-borne apoptotic
cells in spleen.
Antigen presentation in peripheral LNs is thought to be
a process that is coordinately performed by migratory DCs
from peripheral tissues and LN-resident APCs (Allan et al.,
2006; Allenspach et al., 2008; Lee et al., 2009). However, little
is known about the role of different APCs in the clearance ofImmunity 34, 85–95, January 28, 2011 ª2011 Elsevier Inc. 85
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Figure 1. Dead Tumor Cell Vaccination Activates Antitumor Immu-
nity
(A) Expansion of antigen-specific CD8+ T cells in draining LNs. CFSE-labeled
OT-I T cells were injected intravenously into WT mice. OT-I T cell proliferation
in the nondraining (top) and draining (bottom) LNs was analyzed by flow
cytometry 64 hr after the OVA-expressing dead cell injection.
(B) Dead tumor cell vaccination protects mouse from challenge with viable
tumor cells. WT mice were immunized subcutaneously with X-ray-irradiated
EG7 cells in the right flanks. Mice were inoculated with live EG7 cells in the
left flanks 10 days after the vaccination. Mean tumor volumes are shown
with SEM (n = 5 mice/group).
(C) Migration of DCs from skin to draining LNs after antigen injection. Kaede
transgenic mice were injected with PBS, dead cells, or CFA in the hind leg
foot pads. Foot pads were exposed to violet light to induce photoconversion.
Numbers of photoconverted CD11c+ cells in the draining LNs 30 hr after the
injections are shown. Results are mean with SD of six mice/group.
(D) Limited involvement of Langerhans cells and Langerin-positive dermal DCs
in the crosspresentation of dead cell-associated antigens. Proliferation of OT-I
T cells in LNs of WT or Langerin-DTR mice was analyzed by flow cytometry as
described in Experimental Procedures.
Results are representative of at least two independent experiments. *p < 0.05;
n.s., not significant.
Immunity
Antitumor Immunity by CD169+ Macrophagesdead cells and the presentation of dead cell-associated antigens
in peripheral tissue or LNs.
Here we document how tumor cell-associated antigens
derived from dead tumor cells are crosspresented in the draining
LNs. We concluded that CD169+ macrophages that reside in the
LN sinus take up dead tumor cells and directly crosspresent
tumor antigens to CTLs. Mice lacking CD169+ macrophages at
the time of dead tumor cell vaccination or chemotherapy-
induced tumor degradation fail to induce antitumor immunity.
Surprisingly, neithermigratory DCs nor LN-resident conventional
CD8a+ DCs, cells well known for their crosspresentation ability,
are involved in the crosspresentation of dead cell-associated
antigens. These findings should improve our understanding of
how to generate and activate tumor-specific T cell immunity in
response to tumor cell death.
RESULTS
Subcutaneous Immunization with Dead Tumor Cells
Activates Tumor-Specific CTL
The generation of tumor antigen-specific CTLs is an essential
component of tumor immunity. As has been previously reported,
subcutaneous injection of dead cells induced the proliferation of
tumor antigen-specific CTLs in the draining LNs (Figure 1A). After
the subcutaneous immunization with dead tumor cells, dead
cell-associated antigens are transported to the draining LN in
some manner, where they are crosspresented by APCs to acti-
vate tumor-specific CTLs. This immunization with dead tumor
cells serves as an effective tumor ‘‘vaccination,’’ as shown by
the fact that mice injected with X-ray-irradiated EG7 cells, oval-
bumin (OVA)-transfected T cell thymoma, reject subsequently
inoculated syngenic tumor cells (Figure 1B).
Migratory DCs Are Not Primarily Involved in the Delivery
and Crosspresentation of Dead Cell Antigens
APCs in LNs consist of migratory DCs from peripheral tissues
and LN-resident cells. Early studies have demonstrated the
involvement of migratory DCs in the delivery and/or presentation
of various types of antigens in LNs. Waithman et al. (2007)
reported that a cellular antigen derived from dead cells in the
course of natural tissue turnover is delivered and crosspresented
in LNs by skin-derived DCs. Allan et al. (2006) demonstrated that
migratory DCs in the skin transport viral antigens to draining LNs,
where they transfer antigens to LN-resident DCs. These studies
initially led us to assume that immunized dead tumor cell-asso-
ciated antigens would be taken up and transported to LNs by
migratory DCs.
To analyze the contribution of migratory DCs to the delivery of
cellular antigens, we first utilized Kaede transgenic (Tg) mice that
express a photoconvertible fluorescent protein (Tomura et al.,
2008). Kaede mice were immunized with complete Freund’s
adjuvant (CFA) or apoptotic tumor cells in the hind leg foot
pads. At 12 and 18 hr after immunization, the foot pads were
exposed to violet light to induce photoconversion. In control
mice, a small but detectable number of photoconverted
CD11c+ cells were observed in the draining LNs (Figure 1C), indi-
cating the constant migration of these cells from peripheral
tissues to the draining LNs in the steady state. When the mice
were injected subcutaneously with CFA, the number of migratory86 Immunity 34, 85–95, January 28, 2011 ª2011 Elsevier Inc.CD11c+ cells was greatly increased. On the other hand, the
subcutaneous injection of dead cells did not stimulate the
migration of CD11c+ DCs (Figure 1C). This finding indicates
that migratory DCs do not primarily participate in the delivery
of dead cell-associated antigens.
To further analyze the ability of migratory DCs to present
cellular antigens, we next used Langerin-diphtheria toxin
receptor (DTR) mice (Kissenpfennig et al., 2005). In those mice,
diphtheria toxin (DT) injection causes the selective deletion of
Langerhans cells and dermal DCs (Bursch et al., 2007; Poulin
et al., 2007). OT-I OVA-specific T cells were transferred into
wild-type (WT) or Langerin-DTR mice. 2 days after DT injection
into the mice, OVA-expressing apoptotic cells were injected
AB
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Figure 2. Phagocytosis of Dead Tumor Cells by
CD169+ Macrophages in LNs
(A) Tracking of subcutaneously administered dead tumor
cells. PKH26-labeled dead cells were injected subcutane-
ously into the foot pads. Cryosections of draining LNs at
the indicated time points were observed under a fluores-
cence microscope.
(B) Cryosections of draining LNs resected 24 hr after the
dead tumor cell injection were stained with (top right) or
without (top left) anti-CD169. The areas enclosed in boxes
in the top panels are shown at highermagnification in lower
panels.
(C) CD169+ sinus macrophages phagocytose dead tumor
cells via lymphatic flow. PKH-labeled dead cells were in-
jected subcutaneously into the foot pads. 24 hr later, whole
phagocytes in the draining LNs were enriched bymagnetic
sorting. Histogram overlays represent PKH intensities of
phagocytes from draining (line) or nondraining (shaded
area) LNs. Numbers are the percentages of PKH-positive
phagocytes in the draining LNs. These results are repre-
sentative of three independent experiments.
Immunity
Antitumor Immunity by CD169+ Macrophagesinto the foot pads. As shown in Figure 1D, proliferation of OT-I
cells was similar in WT and Langerin-DTR mice.
We blocked the migration of skin DCs in dead cell-injected
mice by the prostaglandin analog BW245C (Angeli et al., 2001).
Allan et al. (2006) demonstrated that viral antigen-specific
CTL priming in the LN was inhibited by blocking skin DC migra-
tion. As shown in Figure S1 available online, treatment with
BW245C did not inhibit the proliferation of OT-I T cells, support-
ing the idea of DC migration-independent delivery of dead cell
antigens.
Taken together, it appears that the roles of migratory cells in
the transport and presentation of dead cell-antigens are limited.
However, a small contribution of migratory DCs, particularly
Langerin-negative dermal DCs, in the dead cell-antigen delivery
and transfer cannot be ruled out.
Phagocytosis of Dead Tumor Cells by CD169+
Macrophages in LNs
We then explored the possibility that the cellular antigens directly
transit to draining LNs. We injected fluorescently labeledImmunity 34apoptotic cells into the foot pads of mice and
then examined the draining LNs at various time
points for the appearance of the labeled cells.
The apoptotic cell corpses reached the draining
LNs as early as 3 hr after the injection (Figure 2A).
The accumulation of dead cells continued up to
4 days after the injection (Figure S2A). This time
course suggests that the arrival of injected
dead cells at the draining LNs precedes that
of migratory DCs, which take days to reach
draining LN (Kissenpfennig et al., 2005). Immu-
nohistochemical examination revealed that the
fluorescent cells were mainly located in the
subcapsular and paracortical sinus and not in
T and B cell areas (Figure 2B). On the basis of
confocal microscopic analysis, dead cell anti-
gens accumulated in the sinus were actually
phagocytosed by CD169+ macrophages in vivo(Figure S2B). This distribution indicates that the cell corpses
traveled to the draining LNs shortly after the injection via
lymphatic flow and were trapped in the sinus by CD169+
macrophages.
We next determined which cells phagocytosed the apoptotic
cell corpses. Two types of phagocytes are present in LNs:
CD11b+CD169+ sinus macrophages and CD11c+ DCs. We iso-
lated total phagocytes from LNs by enriching CD11b- and/or
CD11c-positive cells by magnetic beads. Flow cytometric anal-
ysis of these cells revealed that CD169+ sinus macrophages
could be further divided into CD11c+ and CD11c subpopula-
tions, whereas CD169CD11c+ conventional DCs consisted of
CD8a+ and CD8a subpopulations. 24 hr after the injection of
fluorescence-labeled dead cells, approximately 25% of both
CD11c+ and CD11cCD169+ macrophages contained fluores-
cence-labeled apoptotic cells (Figure 2C). In contrast to this
extensive phagocytosis by CD169+ macrophages, dead cell
phagocytosis by CD8a+ DCs was minimal and only 7% of
CD8a DCs phagocytosed dead cells. These results clearly indi-
cate that subcutaneously injected dead cells reach LNs via, 85–95, January 28, 2011 ª2011 Elsevier Inc. 87
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Figure 3. Failure of Antitumor Immunity in CD169-
DTR Mice
(A) Mice that lack CD169+ macrophages at the time of
vaccination fail to reject viable tumor cells. WT or
CD169-DTR mice were administered with DT on day 2.
Mice were immunized with X-ray-irradiated EG7 cells in
the right flank or untreated on day 0. Live EG7 cells were
inoculated in the left flank on day 14. Mean tumor volumes
are shownwith SEM. n = 10WT or n = 13CD169-DTRmice
per group.
(B) CD169+ macrophages are required for immune activa-
tion subsequent to tumor degradation. WT or CD169-DTR
mice were each inoculated or not inoculated with EG7
cells in the right flank on day 0. The mice were treated
with systemic oxaliplatin on day 7 and LN cells draining
dead tumor cells were restimulated in vitro with OVA on
day 12. Concentrations of IFN-g in the culture medium
weremeasured by ELISA.Mean concentrations are shown
with SD. n = 3 WT without EG7 and n = 4 WT and CD169-
DTR mice with EG7 per group.
(C) CD169+ macrophages are required for the crosspre-
sentation of dead cell-associated antigens. CFSE-labeled
OT-I T cells were injected intravenously into WT or CD169-
DTRmice. OVA-expressing dead cells or OVA in CFAwere
injected subcutaneously into foot pads of DT-treated
mice. Proliferation of OT-I T cells in the draining LNs was
analyzed.
(D) OT-I cells were transferred into WT and CD169-DTR
mice. The DT-treated mice were immunized with X-ray-
irradiated EG7 cells in the flank and were rechallenged
with live EG7 cells in the foot pads. 2 days after this injec-
tion, numbers of CD8+ T cells in the draining and nondrain-
ing LNs were quantitated. Numbers of CD8+ T cells in
draining LNs are divided by those in nondraining LNs.
Mean values are shown with SD of three mice/group.
Dotted line indicates baseline amounts in naive mice.
Results are representative of two independent experi-
ments. *p < 0.05, n.s., not significant.
Immunity
Antitumor Immunity by CD169+ Macrophageslymphatic flow and are predominantly taken up by CD169+
macrophages.
We examined whether CD169+ macrophages migrated from
peripheral tissue into LNs after dead cell injection. First, injection
of dead cells did not increase the population of CD169+ cells in
the draining LNs (Figure S2C). We next quantitated the percent-
ages of photoconverted CD169+ macrophages in the LNs of
Kaede transgenic (Tg) mice. As was shown in Figure 1C, CFA
injection induced robust migration of DCs into draining LN.
Even under this condition, the percentage of photoconverted
cells was very low among CD169+ cells (Figure S2D). These find-
ings indicate that CD169+ macrophages reside in LNs and are
not migratory.
Failure of Antitumor Immunity in CD169-DTR Mice
Given the selective phagocytosis of dead cells by CD169+
macrophages, it became imperative to examine the role of
these macrophages in the crosspresentation of dead tumor
cell antigens. We previously generated genetically targeted
mice expressing the diphtheria toxin receptor (DTR) under the
control of the CD169 gene (CD169-DTR mice) (Miyake et al.,
2007). In these mice, DT injection induced the transient deletion
of macrophages located in the MZ of the spleen. We also found
that CD169+ sinus macrophages were completely depleted in88 Immunity 34, 85–95, January 28, 2011 ª2011 Elsevier Inc.LNs of CD169-DTR mice treated with DT. This deletion was
maintained for up to 7 days after DT injection (Figures S3A–
S3C). On the other hand, DT administration neither depleted
B cells or T cells nor changed the proportions of CD8a+ and
CD8a DCs in the LNs (Figures S3B and S3C).
As we have already shown in Figure 1B, mice immunized with
dead tumor cells are protected from subsequent challenge with
live tumor cells. Remarkably, however, mice depleted of CD169+
macrophages at the time of immunization could no longer reject
viable tumor cells (Figure 3A).
It is assumed that injection of dead tumor cells killed ex vivo by
X-ray irradiation mimic the generation of dead tumor cells by
X-ray irradiation or by chemotherapy. Based on the results
obtained with the tumor vaccination model, we hypothesized
that the induction of antitumor immunity by tumor degradation
in vivo might also be controlled by CD169+ macrophages. In
order to prove this idea, we examined the role of CD169+ macro-
phages in immune activation subsequent to degradation of the
established tumors. Kroemer and his colleagues revealed that
EG7 tumor killed by systemic oxaliplatin primed CD8+ T cells
from the tumor-draining LNs for interferon-g (IFN-g) production
(Ghiringhelli et al., 2009). WT and CD169-DTR mice bearing
established tumors were intraperitoneally injected with oxalipla-
tin to induce tumor degradation. Tumor-draining LN cells were
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Figure 4. Direct Crosspresentation of Dead Tumor Cell-Associated
Antigens by CD169+ Macrophages
(A) WT or CD169-DTR mice were injected intraperitoneally with DT. OVA-
expressing dead cells were injected subcutaneously into the foot pads
2 days after the DT administration. The draining LNs were resected 24 hr later.
Total APCs were enriched by magnetic beads. 1–10 3 104 unfractionated
APCs were cocultured in vitro with OT-I T cells for 42 hr. Proliferation of
T cells was measured in terms of [3H]-thymidine incorporation during the last
18 hr of culture.
(B) Total APCs and OT-I T cells were cocultured in vitro as in (A) for 72 hr. IFN-g
concentration in the culture supernatant was measured by ELISA.
(C) APCs in the skin-draining LNs. Total APCs were divided into two subsets of
CD169+ macrophages and dendritic cells on the basis of CD11c, CD169, and
CD8a expression.
(D) OVA-expressing dead cells were injected subcutaneously into the foot
pads in WT mice. 24 hr later, total APCs were enriched from draining LNs
and further sorted by flow cytometry into four populations as shown in (C).
Fractionated APCs were cocultured with OT-I cells as in (A).
Results in (A), (B), and (D) aremeanwith SD of triplicates and are representative
of at least two independent experiments. *p < 0.005.
Immunity
Antitumor Immunity by CD169+ Macrophageseither restimulated or not restimulated with OVA protein. In
parallel with the finding obtained from the tumor vaccination
model, tumor degradation-induced CD8+ T cell activation was
abolished in CD169+ macrophage-depleted mice (Figure 3B).
These results highlight the critical role of CD169+ macro-
phages in the induction of antitumor immunity both by vaccina-
tion with tumor cells killed ex vivo and by degradation of the
established tumors in vivo.
Next, we analyzed theCD8+ T cell response to various forms of
antigen in CD169+macrophage-depletedmice. OT-I T cells were
transferred into WT or CD169-DTR mice, which were then
immunized subcutaneously with OVA emulsified in CFA or with
OVA-expressing apoptotic cells. Immunization with the OVA-
expressing apoptotic cells failed to induce OT-I T cell prolifera-
tion in CD169+ macrophage-depleted mice, whereas T cell
proliferation was unimpaired in CD169+ macrophage-depleted
mice immunized with OVA in the form of a soluble protein (OVA
in CFA) (Figure 3C). These in vivo data clearly demonstrate that
CD169+ sinus macrophages are required for antigen-specific
T cell proliferation specifically in response to cell-associated
antigens.
We further compared the efficacy of dead tumor cell vaccina-
tion between WT and CD169-DTR mice in terms of CD8+ T cell
proliferation in response to challenge with live tumor cells. OT-I
cells were transferred into WT and CD169-DTR mice. Then, the
mice were immunized in the right flank with dead EG7 cells. 10
to 14 days after the immunization, mice were injected subcuta-
neously with live EG7 cells in the left foot pads. 2 days later,
numbers of CD8+ T cells in the draining (left) and nondraining
(right) LNs were quantitated. In the immunized WT mice, CD8+
T cells vigorously responded to rechallenge with live tumor cells,
indicating effective priming with dead tumor cells. On the other
hand, CD8+ T cells in DT-treated CD169-DTR mice did not
respond to challenge with live tumor cells (Figure 3D). These
results clearly demonstrate the requirement of CD169+ sinus
macrophages for the efficient priming of CD8+ T cells against
dead cell-associated antigens.
Direct Crosspresentation of Cellular Antigens
by the CD169+ Macrophage CD11c+ Subset
We next analyzed the in vitro cell-associated antigen-presenta-
tion activity of APCs in CD169-DTR mice. Total LN phagocytes
from mice injected with OVA-expressing dead cells were en-
riched by magnetic beads and then cocultured in vitro with
OT-I cells. APCs from DT-treated CD169-DTRmice were unable
to crosspresent dead cell-associated OVA to CD8+ T cells, as
assessed by [3H]-thymidine incorporation (Figure 4A) and by
IFN-g production (Figure 4B). In contrast, when the total APCs
were cocultured in vitro with dead cell OVA, CD169-DTR APCs
were comparable presenters to WT APCs (Figure S4A). These
observations suggest that conventional CD11c+ DCs are intact
in their ability to crosspresent dead tumor cell-associated anti-
gens in CD169+ macrophage-depleted mice, but they do not
have access to these antigens accumulated in the LN sinus.
To directly address whether CD169+ macrophages can cross-
present dead cell-associated antigens, we purified these cells by
flow cytometry on the basis of CD169 and CD11c expression
(Figure 4C, top; Figure S4B). As shown in Figure 4D, CD11c+
CD169+ macrophages exhibited the strongest presentationability while the CD11c subset had no presentation ability. We
also examined the CD169CD11c+ DC subpopulation (Fig-
ure 4C, bottom) and found that their ability to present cellular
antigens was significantly lower than that of the CD11c+CD169+
macrophages (Figure 4D). In the crosspresentation of dead cell
antigens transported via lymphatic flow, CD11c+CD169+macro-
phages autonomously accomplished the task without coordina-
tion with DCs because the addition of CD8a+ DCs did not
enhance the antigen-presentation ability of CD11c+CD169+Immunity 34, 85–95, January 28, 2011 ª2011 Elsevier Inc. 89
Figure 5. CD11c, CD169 Double-Positive Macrophages Are Located at the Boundary between the LN Sinus and the T Cell Zone or B Cell
Follicle
10 mm thick cryosections of peripheral LN were stained for CD169 (green), CD11c (red), and B220 (blue) and were observed under a confocal microscope. Areas
enclosed in dashed boxes in (A) and (B) are shown at highermagnification in (B) and (C), respectively. Arrowheads indicate CD11c, CD169 double-positivemacro-
phages. Scale bar represents 50 mm.
Immunity
Antitumor Immunity by CD169+ Macrophagesmacrophages (Figure S4C). These results indicate that CD11c+
CD169+ macrophages phagocytose dead tumor cells trans-
ported to the LN via lymphatic flow and crosspresent cell-asso-
ciated antigens in LNs to stimulate CD8+ T cell proliferation.
However, these findings do not exclude the possibility that
CD11cCD169+ macrophages play some role in the priming of
T cells against cellular antigens, for example by participating in
the retention of cellular antigens in the LN sinus.
It was a mystery how macrophages that capture lymph-borne
antigens in the sinus meet T cells in the parenchyma until two
different groups demonstrated the migration of that T cells
from T cell zone to the sinus to receive antigen presentation.
In vivo real-time imaging analysis showed T cells probe the
surface of cortical sinus and are retained at CD169+ macro-
phage-rich regions (Grigorova et al., 2009). It has recently been
demonstrated that memory OT-I T cells accumulate in the sinus
to form stable conjugate with CD169+ macrophages as early as
5 hr after the subcutaneous administration of OVA-expressing
Toxoplasma gondii (Chtanova et al., 2009).
In order to examine the interaction between CD169+ macro-
phages and antigen-specific CD8+ T cells, the kinetics of CD8+
T cells in LN were analyzed sequentially after the subcutaneous
injection of dead cells. We transferred carboxyfluorescein succi-
nimidyl ester (CFSE)-labeled CD8+ T cells from OVA-immunized
OT-I mice into wild-type mice. The mice were subcutaneously
injected with OVA-expressing dead cells and draining LNs
were analyzed by immunohistochemistry 4 to 24 hr after the
injection. This analysis showed that the number of OT-I T cells
that conjugate with CD169+ macrophages peaked at 4 hr after
the injection of dead cells and rapidly decreased thereafter (Fig-
ure S5A). Fluorescence and confocal microscopic observations
indicate that OT-I T cells are in close contact with CD169+
macrophages at 4 hr (Figures S5B and S5C). These results
strongly suggest that CD8+ T cells relocalize in the sinus rapidly
after the challenge with dead cells to receive antigen presenta-
tion from CD169+ macrophages and then return to the T zone
for proliferation.90 Immunity 34, 85–95, January 28, 2011 ª2011 Elsevier Inc.Distinct Localization and Function of CD11c+CD169+
Sinus Macrophages
The differences in cell surface marker profile and antigen-
presentation activity suggest that the two CD169+ macrophage
subpopulations have distinct localization and functions.
We first examined the localization of the CD11c+CD169+
subpopulation. Immunohistochemical analysis by costaining
with CD11c and CD169 antibodies revealed that CD169+ cells
were exclusively localized in the sinus, whereas CD11c+ cells
were mainly localized in the T cell zone (Figure 5A). However,
a small number of CD169+ cells were found to coexpress
CD11c. These double-positive cells were mainly localized in
the cortical and paracortical sinus, especially at the boundary
between the sinus and the T cell zone or B cell follicle (Figures
5B and 5C).
Next we compared the expression of various surface mole-
cules between two fractions of CD169+ macrophages (Fig-
ure S6) to find that they uniformly expressed CD11b and F4/
80, indicating that they were indeed macrophages. They were
positive also for major histocompatibility complex (MHC) and
costimulatory molecules that are required for efficient T cell
activation.
To further explore the functional differences between the two
CD169+ macrophage subpopulations, we analyzed their cyto-
kine production profiles. Both populations were enriched by
magnetic beads, further purified by a cell sorter, and then stim-
ulated with toll-like receptor (TLR) ligands such as LPS or CpG
in vitro. We measured the concentrations of a panel of cytokines
with a cytokine array. LPS (Figure 6A) or CpG (Figure 6B) stimu-
lation induced the production of IL-1b, IL-12 p40, IL-12 p70,
MIP-1a, and RANTES by the CD11c+CD169+ subset (Figure 6,
filled bars). On the other hand, the concentrations of these cyto-
kines in the culture medium of CD11c subset were generally
lower than those of the CD11c+ subset (Figure 6, open bars)
or undetectable. These results clearly indicate that the two
CD169+ macrophage subsets have distinct cytokine production
profiles on stimulation with TLR ligands.
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Figure 6. Cytokine Production Profiles of CD11c-Positive and -Negative CD169+ Macrophages
CD169+ macrophages were purified from LNs of WT mice with a combination of magnetic beads and cell sorting. Purified macrophages were stimulated in vitro
with LPS (A) or CpG (B). Concentrations of cytokines were measured by cytokine array. Assays were performed in triplicate and mean values are shown with SD.
*p < 0.05. Filled bars, CD11c+CD169+ macrophages; open bars, CD11cCD169+ macrophages.
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by CD11c+CD169+ Macrophages
In general, macrophages recognize phosphatidylserine (PS)
exposed on the surface of apoptotic cells in order to engulf
apoptotic cells. We have previously shown that a milk fat
globule-EGF-factor 8 (MFG-E8) protein with a point mutation in
an Arg-Gly-Asp (RGD) motif (D89E) inhibited apoptotic cell
engulfment by masking PS (Asano et al., 2004; Hanayama
et al., 2002). To define the molecular mechanisms of apoptotic
cell phagocytosis by CD11c+CD169+ macrophages, we exam-
ined the effects of D89E on this process. Apoptotic cells were
incubated with D89E and then injected subcutaneously into
WT mice. As shown in Figure 7A, D89E treatment significantly
inhibited the phagocytosis of apoptotic cells by both CD11c
and CD11c+CD169+ macrophages, whereas treatment with
E1E2PT, another MFG-E8 mutant protein that does not bind to
PS, had no effect on phagocytosis. As another assay for the
impact of masking PS on dead cells, we analyzed antigen-
specific T cell proliferation and found that it was greatly reduced
by D89E treatment (Figure 7B). These results clearly indicate that
CD169+ macrophages phagocytose dead cells in a PS-depen-
dent manner, and this phagocytosis is required for the crosspre-
sentation of cell-associated antigens by CD169+ macrophages
in LNs.
DISCUSSION
During the course of tumor growth, a substantial fraction of
tumor cells continually undergo apoptosis. In addition to
this constant cell death, irradiation or administration of anti-
cancer drugs causes apoptosis of a large number of tumorcells. It is well accepted that apoptosis is a ‘‘silent’’ cell death
that does not trigger immune responses. Rather, the efficient
removal of apoptotic cells by phagocytes frequently results in
tolerance toward cell-associated antigens. Thus, apoptosis
induced by anticancer drugs is accompanied by immunosup-
pressive side effects. At the same time, it has long been
known that the subcutaneous immunization with irradiated
syngeneic tumor cells protects mice from subsequent chal-
lenge with the same tumor in viable form. Casares et al.
(2005) found that tumor cell death induced by anthracyclin,
a class of anticancer drugs, or by X-ray irradiation promoted
tumor-specific CTL activation. This conversion from tolero-
genic into immunogenic cell death was dependent on the
exposure of calreticulin on the tumor cell surface and/or the
release of endogenous adjuvants from dead cells (Apetoh
et al., 2007; Obeid et al., 2007). It is most likely that these
immunogenic cell corpses enhance the activation state of
APCs. However, APCs that are responsible for the crosspre-
sentation of dead tumor cell-associated antigens have until
now not been identified. Our studies here show that (1)
subcutaneously injected dead cells are transported to LNs
via lymphatic flow and (2) macrophages lining the LN sinus
phagocytose and directly crosspresent dead cell-associated
antigens to CD8+ T cells. This presentation is critical for the
proliferation and activation of tumor-specific CD8+ T cells
because mice lacking CD169+ macrophages at the time of
vaccination are unable to reject viable tumor cells. Systemic
treatment with anticancer chemotherapy induces massive
degradation of solid tumor, and dead tumor cell-associated
antigens thus generated in the peripheral tissue prime CD8+
T cells in the tumor-draining LNs (Ghiringhelli et al., 2009).Immunity 34, 85–95, January 28, 2011 ª2011 Elsevier Inc. 91
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Figure 7. CD169+ Macrophages Phagocytose Dead Cells in a PS-
Dependent Fashion
(A) Phagocytosis of dead tumor cells by CD169+ macrophages is PS depen-
dent. PKH26-labeled dead W3-OVA cells were coated either with D89E or
E1E2PT. Draining LNs were resected 24 hr after the dead cell injection. Total
APCs were stained for CD169 and CD11c. Numbers are the percentages of
PKH-positive macrophages. Average values of three mice/group are shown
with SD. *p < 0.05.
(B) Blocking of phagocytosis of dead tumor cells impairs antigen-specific
CD8+ T cell proliferation. CFSE-labeled OT-I cells were injected intravenously
into WT mice. OVA-expressing dead cells incubated either with PBS, D89E, or
E1E2PTwere injected subcutaneously into the foot pads. OT-I cell proliferation
in the draining LNs was analyzed by flow cytometry. These results are repre-
sentative of four to six different mice in each group.
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to tumor degradation in vivo is also controlled by CD169+
macrophages.92 Immunity 34, 85–95, January 28, 2011 ª2011 Elsevier Inc.Based on a criteria introduced recently by different groups
(Junt et al., 2007; Phan et al., 2009), we defined CD169-positive
cells that reside in the lymph node sinus as ‘‘CD169-positive
macrophages.’’ Although these cells express generally accepted
macrophage markers, it remains to be determined whether
CD11c+CD169+ macrophages constitute a small subset of
CD8a+ DCs.
Very recently, Phan et al. (2009) focused on the function of
CD11cCD11b+CD169+ subcapsular sinus macrophages and
found that these cells captured the immune complexes and
relayed them to B cell follicles without digestion. In the present
study, we showed that subcutaneously injected dead cells
were captured by both CD11c+ and CD11cCD169+ macro-
phages, but only the CD11c+ subset crosspresented these
antigens. As far as we know, this is the first work to identify
crosspresenting APCs that reside exclusively in the LN sinus.
As described above, the immunogenicity of dead tumor cells
depends on the mode of cell death, and even apoptotic cells can
become immunogenic under certain circumstances (Tesniere
et al., 2008). To better understand antitumor immune regulation,
it is very important to explore how immunogenic dead cells
affect the function and activation status of CD169+ macro-
phages. In addition to dead cells, particulate matter, such as
bacteria, viruses, parasites, and large immune complexes, accu-
mulates in the LN sinus (Carrasco and Batista, 2007; Chtanova
et al., 2008; Junt et al., 2007; Phan et al., 2007). Therefore, it
will be of great interest to examine the ability of CD11c+CD169+
macrophages to present antigens derived from particulate
matter.
The LN sinus is a highway that links afferent and efferent
lymph and is believed to be a filtering zone for lymph-borne
molecules. Large particles, including cellular antigens in the
lymphatic fluid, make initial contact with CD169+ macrophages
that serve as sentinels located along the length of the LN
sinus. It is noteworthy that CD8a+ conventional DCs, which
are well known for their potent crosspresentation activity
(Schnorrer et al., 2006), are not predominantly involved in the
crosspresentation of dead cell-associated antigens trans-
ported via lymphatic flow. These conventional DCs in LNs
are located in the T cell areas, so they may not have access
to dead cells that accumulate in the LN sinus. In contrast to
dead cell-associated antigens, the crosspresentation of
soluble antigens took place normally even in the absence of
CD169+ macrophages. It is very likely that soluble antigens
passed the layer of sinus lining cells and directly entered the
T cell area where they were endocytosed by CD8a+ conven-
tional DCs and subsequently crosspresented. This speculation
is consistent with a previous report that macrophages lining
the LN sinus capture particles larger than 70 kDa, whereas
smaller molecules rapidly enter the T and B cell areas via
a conduit system (Roozendaal et al., 2008; Sixt et al., 2005).
Sancho et al. (2009) described CLEC9A as a CD8a+ DC-
expressing receptor for necrotic cells that regulates the cross-
presentation of dead cell-associated antigens. They demon-
strated that CLEC9A-deficient bone marrow (BM) DCs failed
to crosspresent dead cell-associated antigens cocultured
in vitro. It is worth revisiting the contribution of this receptor
in the crosspresentation of subcutaneously injected dead cell
antigens in peripheral LNs.
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transport and crosspresent dead cell antigens that are gener-
ated as a result of tissue turnover. Through the analysis of Kaede
Tg mice, we found that DCs constantly migrate from tissue into
draining LNs under physiological conditions. These observations
implicate that the contribution of migratory DCs, particularly
Langerin-negative dermal DCs that are not depleted in Langerin-
DTR mice, to the delivery and presentation of dead cell antigens
could not be excluded.
In the last two decades, we have witnessed numerous efforts
to develop preventive and therapeutic cancer immunotherapy.
Two main strategies are vaccine therapy and cell transfer
therapy. In the former, tumor antigen-conjugated antibodies
are administered to activate APCs in vivo (Bozzacco et al.,
2007; Sancho et al., 2008; Trumpfheller et al., 2006). Antitumor
immunity achieved by dead tumor cell vaccination may also
be included in this category. The latter therapy includes the
transfer of DCs loaded ex vivo with tumor-specific antigens (Gil-
boa and Vieweg, 2004; Kalergis and Ravetch, 2002; Schuurhuis
et al., 2006; Su et al., 2005). In either case, the primary goal of
the therapies is to enhance tumor-directed T cell responses to
effectively destroy tumor cells. However, it is disappointing
that the effects of these immunotherapies are often compro-
mised by suppressor leukocytes within a tumor (Marigo et al.,
2008; Sica and Bronte, 2007) or by the lack of signals to induce
DC maturation (Gabrilovich, 2004; Melief, 2008). It seems likely
that one problem with current immunotherapies is that they
target DCs that are not primarily responsible for the crosspre-
sentation of dead tumor cell-associated antigens. We have
shown here that CD169+ macrophages directly crosspresent
tumor antigens to CD8+ T cells. This finding provides new insight
into the activation of tumor-directed CTL in LNs, which may help
overcome the limitations of current immunotherapeutic
approaches.
The structure of the spleen is very similar to that of the LN.
In spleen, various types of blood-borne particles, including
apoptotic cells, accumulate in the MZ. Those particles are
rapidly cleared by two types of macrophages, marginal zone
macrophages (MZMs) and marginal metallophilic macrophages
(MMMs), which are thought to be anatomical and functional
counterparts of CD169+ macrophages in the LN. It has not
been possible to isolate viable macrophages from the splenic
MZ for in vitro functional assays. Therefore, only the in situ
phagocytotic activity of these macrophages has been demon-
strated in previous studies. Because the present study revealed
the unique antigen-presentation activity of CD169+ macro-
phages in LNs, it would be beneficial to examine other functions
of these splenic macrophages, such as antigen-presentation
activity.
In conclusion, the present study clearly demonstrates the
essential role of CD169+ macrophages in tumor immunity
induced by tumor cell death and highlights the heterogeneity
and the multifunctionality of CD169+ macrophages in LNs.EXPERIMENTAL PROCEDURES
Mice
All experiments with mice were approved by the RCAI Animal Use Committee
and performed in accordance with applicable guidelines and regulations.Antitumor Vaccination and Assessment of Tumor Growth In Vivo
To induce cell death, EG7 cells were irradiated with 40 Gy X-rays followed by
overnight culture at 37C. This treatment resulted in populations containing
70% Annexin V+ PI+ double-positive cells, as assessed by flow cytometry, at
24 hr. Then, 2–4 3 106 dead cells were injected subcutaneously into the right
flanks of mice. Mice were rechallenged in the left flanks with 1.53 106 live EG7
cells later than 10 days after the injection. Tumor growth was monitored with
calipers for 3 weeks or until the volume of the tumor exceeded 2000 mm3.
Tracking of Subcutaneously Injected Dead Cells
EG7 cells were labeled with 8 mM PKH26 (Sigma) according to the manufac-
turer’s protocol. Cells were irradiated with 40 Gy X-ray to induce cell death.
Then, 1 3 107 labeled dead cells were injected subcutaneously into the flank
and tail base of mice. Draining inguinal LNs resected 3–96 hr after the injection
were processed for cryosections and stained with anti-CD169 (AbD Serotec)
followed by Alexa Fluor 488-labeled anti-rat IgG (Invitrogen) or not stained
before observation under a fluorescence microscope. For confocal micro-
scopic observation, macrophages in the sinus were labeled in vivo by injecting
4 mg of anti-CD169 3 hr before the LN removal. For assessment by flow cytom-
etry, Fas ligand (FasL)-treated OVA-expressing W3 cells (W3-OVA) were
injected subcutaneously. LNs resected 24 hr after the injection were digested
with a mixture of Collagenase IIs (750 mg/ml) and DNase I (10 mg/ml, Sigma) in
HBSS for 25 min at 37C, then homogenized and filtered through nylon mesh
and washed in MACS running buffer (PBS supplemented with 0.5% BSA
and 2 mM EDTA). CD11b- and/or CD11c-positive cells were enriched with
magnetic beads (Miltenyi). Cells were stained with anti-CD169, anti-CD8a,
and anti-CD11c (eBioscience) and analyzed by a flow cytometer (FACS
Calibur; BD Biosciences). Anti-CD169 was labeled with an Alexa Fluor 488
Labeling Kit (Invitrogen). PKH26-positive cells were considered to have phago-
cytosed dead cells and/or to be in direct contact with dead cells.
For the inhibition of phagocytosis by CD169+macrophages, dead cells were
incubated either with 10 mg/ml of D89E, which masks PS on apoptotic cells, or
the same amount of E1E2PT, which does not bind to PS (Asano et al., 2004).
In Vivo T Cell Priming by Systemic Chemotherapy
WT or CD169-DTRmice were each inoculated or not inoculated with 1.03 106
live EG7 cells in the right flank on day 0. Each mouse was injected intraperito-
neally with 40 mg of oxaliplatin on day 7 to induce tumor degradation in vivo.
The mice were injected with DT on day1 and day 6. Tumor-draining brachial,
axillary, and inguinal LNs were removed on day 12 and restimulated in vitro
with 1 mg/ml OVA protein. IFN-g production in the culture medium at 72 hr
was determined with a mouse IFN-g ELISA set (BD Bioscience).
In Vivo Proliferation of OT-I T Cells
OVA-specific OT-I T cells from spleen, mesenteric LN, and skin draining LNs
were enriched with magnetic beads. Cells were labeled with 5 mM CFSE
(Dojindo). Then, 2.5 3 106 T cells were injected intravenously into WT,
CD169-DTR, or Langerin-DTR mice on day 3. In some experiments, 20 ng/g
body weight (CD169-DTR) or 40 ng/g body weight (WT and Langerin-DTR)
of DT was injected intraperitoneally on day 2. Then, 1 3 107 FasL-treated
W3-OVA cells or 100 mg of OVA emulsified in complete adjuvant (CFA; Difco)
were injected subcutaneously into foreleg foot pads on day 0. Draining
brachial LNs were resected on day 2 (56–64 hr after the injection). Dilutions
of CFSE were assessed by flow cytometry.
In Vitro T Cell Proliferation Assay
W3-OVA cells were treated with soluble FasL for 5 hr. Then, 2 3 107 FasL-
treated W3-OVA cells were injected subcutaneously into the footpads of
mice. Draining LNs were resected 20–24 hr after the injection. Total APCs
were enriched with magnetic beads, as described above. Then, 1–10 3 104
unfractionated APCs were cocultured with 2.5 3 105 OT-I T cells in RPMI
supplemented with 10% FCS and 50 mM 2ME in a 96-well flat-bottom plate
for 40–48 hr. For the fractionation of LN phagocytes, total phagocytes were
labeled with Alexa Fluor 488-labeled anti-CD169, PE-labeled anti-CD8a, and
APC-labeled anti-CD11c, followedby cell sorting (FACSAria; BDBiosciences).
Then, 13 105 purified APCs were cocultured with 2.53 105 OT-I T cells in vitro
for 40–48 hr. The incorporation of [3H]-thymidine during the last 16–20 hr ofImmunity 34, 85–95, January 28, 2011 ª2011 Elsevier Inc. 93
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Antitumor Immunity by CD169+ Macrophagesculture was quantitated. IFN-g production in the culture medium at 72 hr was
determined with a mouse IFN-g ELISA set (BD Bioscience).
Immunohistochemistry
OCT-embedded cryosections of LNs were stained and observed under a fluo-
rescent (Keyence) or a confocal microscope (Leica).
Cytokine Array
Concentrations of cytokines in the culture medium of CD169+ macrophages
were measured with cytokine array (Luminex).
Statistical Analysis
All statistical analysis used unpaired two-tailed Student’s t test. p < 0.05 was
considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at doi:10.1016/
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